Immunoassay News and Research

RSS

Chemists' innovation may be a better model for disease diagnostic kits

When someone develops liver cancer, the disease introduces a very subtle difference to their bloodstream, increasing the concentration of a particular molecule by just 10 parts per billion.

29 Oct 2012

FDA clears Roche's automated type-specific herpes tests

Roche announced today that it has received clearance from the U.S. Food and Drug Administration for its IgG Antibody to herpes simplex virus types 1 and 2 assays for use on cobas modular platforms. The tests are intended for use with sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV-1 and HSV-2 infection.

From Roche Sequencing and Life Science 5 Sep 2012

Abbott receives CE Marking for ARCHITECT testosterone assay

Abbott announced today CE Marking (Conformite Europeenne) for a testosterone assay with improved sensitivity and clinical utility.

28 Aug 2012

Salivary IL-6 could predict recurrence after surgery in mouth cancer patients

Salivary levels of the proinflammatory cytokine interleukin-6 could be a useful predictor for locoregional recurrence in oral squamous cell carcinoma patients who are treated surgically, report researchers.

23 Aug 2012

New HIV test helps researchers determine incidence, whether prevention strategies work

The Centers for Disease Control and Prevention (CDC) has developed a new HIV test, called the Limiting Antigen Avidity Enzyme Immunoassay, that can tell whether a person contracted the virus within the last 141 days, "hugely important information for researchers, who need to know whether fewer people are becoming newly infected with HIV to determine whether a prevention program is working," the Wall Street Journal's "Health Blog" reports.

9 Aug 2012

University of Nevada researcher to optimize new rapid test for melioidosis

A new rapid test to diagnose melioidosis, a difficult infection to treat - and classified as a biothreat by the Centers for Disease Control and Prevention - is being optimized and tested by University of Nevada School of Medicine researcher David AuCoin.

9 Aug 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

LSDF announces $570,000 in awards to support commercialization of new health-related products

The Life Sciences Discovery Fund (LSDF) today announced nearly $570,000 in awards in its inaugural corporate grant program to support commercialization of new health and health-care products by four early-stage Washington-based companies.

25 Jul 2012

T2Hemostasis provides reliable and rapid results when compared to conventional systems

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of new data on hemostasis monitoring at the American Association for Clinical Chemistry Annual Meeting, July 15-19, 2012, in Los Angeles, CA.

20 Jul 2012

Abbott to showcase new informatics and lab solutions at AACC annual meeting

Abbott will feature new solutions to improve data management and automation at this year's American Association for Clinical Chemistry (AACC) annual meeting, July 15-19, in Los Angeles, Calif. Solutions to further enhance efficiency and workflow in today's laboratories will be the focal point of the Abbott exhibit.

16 Jul 2012

Abbott announces CE Marking for ARCHITECT HbA1c assay

More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformite Europeenne) for the Abbott ARCHITECT HbA1c (IA) Assay.

10 Jul 2012

GSD receives FDA clearance for next-generation Lyme disease Line Immunoassay

Gold Standard Diagnostics (GSD) today announced FDA clearance of its next-generation Lyme disease Line Immunoassay which offers excellent specificity and sensitivity at any disease stage.

28 Jun 2012

Beckman Coulter announces PMA from FDA for Prostate Health Index

Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.

From Beckman Coulter Diagnostics 26 Jun 2012

Affymetrix acquires eBioscience

Affymetrix Inc., today announced that the Company has completed its acquisition of eBioscience Holding Company, Inc., a privately-held company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

26 Jun 2012

T2Endotoxin assay extends reach of T2MR detection

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on endotoxin detection at the American Society for Microbiology General Meeting, June 16-19, 2012, in San Francisco, CA.

18 Jun 2012

Roche files TnT-hs assay 510(k) submission with FDA for use on laboratory analyzers

Roche announced today that it has filed a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a fully automated TnT-hs assay for use on Roche's full portfolio of laboratory analyzers.

From Roche Sequencing and Life Science 8 Jun 2012

Breakthrough in nanotechnology could make laboratory tests more sensitive

A laboratory test used to detect disease and perform biological research could be made more than 3 million times more sensitive, according to researchers who combined standard biological tools with a breakthrough in nanotechnology.

2 Jun 2012

SQI Diagnostics reports net loss of $1,350,000 for second quarter 2012

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the three and six months ended March 31, 2012.

31 May 2012

“Sandwich” immunoassay used to search for new chemical reactions

Many discoveries are made by chance, but it is also possible to help it along: The chance of finding something interesting increases when the number of experiments rises. French researchers have now applied this principle to the search for new chemical reactions. In the journal Angewandte Chemie, they have introduced a new concept based on antibodies and a “sandwich” immunoassay.

22 May 2012

Aushon plans global launch of new multiplex protein biomarker platform

Aushon announced its plans today for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance.

21 May 2012